NEW ISSUE: Biogroup €1bn minimum 5.25NC2 sr sec notes on the road
HYC European Market: Deal Flow - General
Issuer:CAB Selas (Biogroup) (Ticker: BIOGRP)
Business: A leading private medical laboratory services player in Europe
Use of Proceeds: Together with €400m cash on balance sheet and a new €1bn minimum TLB, to (i) amend & extend the existing TLB facilities and (ii) refinance the existing EUR1.15bn 3.375% Senior Secured Notes due 01-Feb-28 (callable at 100) and (iii) pay certain costs, fees and expenses in connection with the transactions
Concurrent Exchange: Concurrent exchange offer into the New Notes due 2031 for existing holders of the 3.375% SSN due 2028 and 5.000% SUN due 2029
Joint Global Coordinators and Joint Physical Bookrunners: BNP Paribas (B&D), HSBC, JPM
Joint Global Coordinators and Joint Bookrunners: Citi, CACIB, NTX
Joint Bookrunners: DB, GS
Target Market: MiFID II professionals/ECPs-only/No PRIIPs KID – Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail in EEA.